MIL 97
Alternative Names: MIL-97Latest Information Update: 16 Feb 2024
At a glance
- Originator Beijing Mabworks Biotech
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 13 Feb 2024 Cancer Institute and Hospital, Chinese Academy of Medical Sciences plans phase-II trial for Pancreatic cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Combination therapy, Second-line therapy or greater, In adults, In the elderly) in March 2024 (Parenteral) (NCT06255912)
- 18 Jan 2022 Phase-I clinical trials in Solid tumours (Metastatic disease, Late-stage disease, Second-line therapy or greater, Inoperable/Unresectable) in China (IV) (NCT04965077)
- 21 Jul 2021 Beijing Mabworks Biotech plans a phase I trial in Solid tumours (Second-line therapy or greater, Metastatic disease, Late-stage disease)(NCT04965077)